Pharmacogenomic testing for mental health (Part I): Documenting early adopter perceptions of use for eight scenarios

Beatriz Manzor Mitrzyk, Melissa A. Plegue, Reema Kadri, Shivang U. Danak, Joseph D. Hubbard, Emily A. Kaip, Dana N. Roberson, Vicki L. Ellingrod, Karen B. Farris, MacK T. Ruffin, Michael S. Klinkman, Lorraine R. Buis

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Aim: We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). Patients & methods: We conducted a phone survey with prescribers who had previously ordered an Informed PGx (Progenity, Inc., MI, USA) test. Results: We identified 1037 prescribers in our sampling period. Respondents (n = 64) were predominantly female (61.5%) and in pediatrics (n = 42; 64.6%). PGx testing was used for multiple scenarios (mean 3.3 ± 1.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. Conclusion: PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalPersonalized Medicine
Issue number3
StatePublished - May 2021

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Pharmacogenomic testing for mental health (Part I): Documenting early adopter perceptions of use for eight scenarios'. Together they form a unique fingerprint.

Cite this